A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/7068 (2006.01) A61K 9/127 (2006.01) A61K 31/4745 (2006.01) A61K 31/704 (2006.01) C12Q 1/00 (2006.01) G01N 33/15 (2006.01)
Patent
CA 2581133
The use of the maximum tolerated dose (MTD) of individual drugs to determine appropriate administration ratios of drugs for combination therapy, wherein the ratios of drugs are fixed based on the same percentage of the MTD for each drug. Furthemore, antineoplastic compositions comprising liposomal encapsulated gemcitabine alone or in combination with free or liposomal encapsulated antineoplastic agents, such as idarubicin, irinotecan, etopside, cisplatin, cyclophosphamide, doxorubicin, or vincristine are diclosed.
L'invention expose l'utilisation de la dose maximale tolérée (MTD) de médicaments individuels pour déterminer les proportions d'administration appropriées de médicaments pour une thérapie combinatoire, ces proportions de médicaments étant déterminées sur la base du même pourcentage de MTD pour chaque médicament. L'invention expose en outre des compositions antinéoplasiques comprenant de la gemcitabine encapsulée dans des liposomes seule ou en association avec des agents antinéoplasiques libres ou encapsulés dans des liposomes tels que l'idarubicine, l'irinotécan, l'étoposide, le cisplatine, le cyclophosphamide, la doxorubicine ou la vincristine.
Bally Marcel
Dos Santos Nancy
Ramsay Euan
British Columbia Cancer Agency
Oyen Wiggs Green & Mutala Llp
LandOfFree
Free or liposomal gemcitabine alone or in combination with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Free or liposomal gemcitabine alone or in combination with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Free or liposomal gemcitabine alone or in combination with... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1970899